Abstract

High Content Screening With hiPSC-Derived Neurons

Amanda Cobos-Correa, Lab Head Screening Sciences, Novartis Institutes for Biomedical Research

Fragile X Syndrome (FXS) is the most common form of inherited mental retardation and it is caused in the majority of cases by epigenetic silencing of the Fmr1 gene. Today, no specific therapy exists for FXS and current treatments are only directed to improve behavioral symptoms. Neuronal progenitors derived from FXS patient-induced pluripotent stem cells (iPSCs) represent a unique model to study the disease and develop assays for large scale drug discovery screens since they conserve the Fmr1 gene silenced within the disease context. We have established a high content imaging assay to run a large-scale phenotypic screen aimed to identify compounds that reactivate the silenced Fmr1 gene. A set of 50000 compounds was tested including modulators of several epigenetic targets. We describe an integrated drug discovery model comprising iPS generation, culture scale-up and quality control and screening with a very sensitive high content imaging assay assisted by single cell image analysis and multi-parametric data analysis based on machine learning algorithms. The screening identified several compounds that induced a weak expression of FMRP and thus, sets the basis for further large-scale screens to find candidate drugs or targets tackling the underlying mechanism of FXS with potential for therapeutic intervention [M. Kaufmann et al. J Biomol Screen 2015;20:1101-1111].